Journal article
Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E–mutant metastatic colorectal cancer: Safety lead-in results from the phase III BEACON Colorectal Cancer Study
E Van Cutsem, S Huijberts, A Grothey, R Yaeger, PJ Cuyle, E Elez, M Fakih, C Montagut, M Peeters, T Yoshino, H Wasan, J Desai, F Ciardiello, A Gollerkeri, J Christy-Bittel, K Maharry, V Sandor, JHM Schellens, S Kopetz, J Tabernero
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019
DOI: 10.1200/JCO.18.02459
Abstract
PURPOSE To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E–mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial (ClinicalTrials.gov identifier: NCT02928224; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). PATIENTS AND METHODS Before initiation of the randomized portion of the BEACON Colorectal Cancer trial, 30 patients with BRAF V600E–mutant mCRC who had experienced treatment failure with one or two prior regimens were to be recruited to a safety lead-in of encorafenib 300 mg daily, binimetinib 45 mg twice dail..
View full abstractGrants
Funding Acknowledgements
We thank the patients, their families, and the sites that participated in this study. For editorial support, funded by Array BioPharma, we thank Philip Sjostedt from The Medicine Group LLC, a Division of Bespoke Communications.